Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
9.41
-0.02 (-0.21%)
At close: Nov 26, 2025, 4:00 PM EST
9.30
-0.11 (-1.17%)
After-hours: Nov 26, 2025, 6:38 PM EST
DAWN Revenue
Day One Biopharmaceuticals had revenue of $39.80M in the quarter ending September 30, 2025, a decrease of -57.56%. This brings the company's revenue in the last twelve months to $133.67M, up 31.11% year-over-year. In the year 2024, Day One Biopharmaceuticals had annual revenue of $131.16M.
Revenue (ttm)
$133.67M
Revenue Growth
+31.11%
P/S Ratio
7.24
Revenue / Employee
$738,519
Employees
181
Market Cap
966.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131.16M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DAWN News
- 2 days ago - Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - GlobeNewsWire
- 8 days ago - Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 13 days ago - Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout - Benzinga
- 13 days ago - Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases - GlobeNewsWire
- 16 days ago - Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - GlobeNewsWire
- 22 days ago - Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Day One Reports Third Quarter 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 5 weeks ago - Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 - GlobeNewsWire